Test drug levels and TB activity of TMC207 in children
Treatments studied
Part of Infections clinical trials.
This study measures how TMC207 (an anti-TB medicine) works in the body and in combination with standard MDR-TB medicines for children and teens with lung MDR-TB. It may help clinicians learn the safest way to use TMC207 and how well it may support treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a child from birth up to under 18 years old at screening
- Weigh more than 3 kilograms and fit age-based growth ranges on WHO charts
- Have confirmed or likely MDR-TB affecting the lungs, and/or a non-severe type outside the lungs
- Start MDR-TB treatment on Day 1, or start within 12 weeks of Day 1, and be open to changing the plan for TMC207 use
- Stop rifampin (RMP) at least 7 days before the baseline visit
- Be willing to do HIV testing (and get the parent’s/ mother’s HIV testing if needed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This study is testing new ways to quickly diagnose TB in children under 15. It aims to find better tests that can be used at clinics, especially for kids who may not have obvious symptoms.
This study tests a new tuberculosis drug called TBD09 combined with other TB medicines in people with newly diagnosed, drug-sensitive TB. The goal is to see if this combination works well and is safe.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This trial tests a new 6-month treatment for people with multidrug-resistant tuberculosis (MDR-TB). It aims to see if this shorter treatment works well and can be used in France, offering a quicker option for recovery.
Hear when a new Tuberculosis, Multidrug-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.